KAPA on NYSE
Kairos Pharma, LTD.
American pharmaceutical preparations company based in Los Angeles. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerKAPA on NYSE1
- IndustryPharmaceutical Preparations1
- HeadquartersLos Angeles, California1
- Incorporated inDE2
- Business address2355 Westwood Blvd. #139, Los Angeles, Ca 900642
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
101 is a small molecule that targets the GITR ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Item 4 brought in 91% of the revenue Kairos Pharma, LTD. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2025 |
|---|---|
| Item 4 | $50.0M |
| Item 1, 2 and 3 | $5.0M |
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $2.1M | $414.0K |
| General and administrative | $3.4M | $1.9M |
| Total operating expenses | $5.6M | $2.3M |
| Loss from operations | -$5.6M | -$2.3M |
| Interest expense | -$35.0K | |
| Debt discount amortization | -$154.0K | |
| Financing costs | -$670.0K | |
| Gain on settlement of accounts payable | $599.0K | |
| Interest income | $125.0K | |
| Total other income (expenses) | $125.0K | -$260.0K |
| NET LOSS | -$5.4M | -$2.6M |
| BASIC LOSS PER COMMON SHARE | -$0.30 | -$0.23 |
| DILUTED LOSS PER COMMON SHARE | -$0.30 | -$0.23 |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC | 18.4M shares | 11.4M shares |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING DILUTED | 18.4M shares | 11.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-04-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $4.5M | $1.3M | ||
| Vendor advances, net | $845.0K | $2.9M | ||
| Prepaid expenses and other current assets | $51.0K | $38.0K | ||
| Total Current Assets | $5.4M | $4.2M | ||
| Deferred offering costs | $1.1M | $1.4M | ||
| Intangible assets, net | $62.0K | $222.0K | ||
| Total Other Assets | $1.2M | $1.6M | ||
| TOTAL ASSETS | $6.5M | $5.8M | ||
| Accounts payable and accrued expenses | $199.0K | $992.0K | ||
| Total Current Liabilities | $199.0K | $992.0K | ||
| Common stock, par value $0.001, 100,000,000 shares authorized; 20,821,353 and 13,736,597 shares issued and outstanding, respectively; | $21.0K | $14.0K | ||
| Additional paid-in capital | $20.6M | $13.6M | ||
| Accumulated deficit | -$14.3M | -$8.8M | ||
| Total Shareholders Equity | $6.3M | $4.8M | -$2.1M | |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $6.5M | $5.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | 20.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 20.8M shares | 13.7M shares | ||
| Common stock, shares outstanding | 20.8M shares | 13.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-04-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $4.5M | $1.3M | ||
| Vendor advances, net | $845.0K | $2.9M | ||
| Prepaid expenses and other current assets | $51.0K | $38.0K | ||
| Total Current Assets | $5.4M | $4.2M | ||
| Deferred offering costs | $1.1M | $1.4M | ||
| Intangible assets, net | $62.0K | $222.0K | ||
| Total Other Assets | $1.2M | $1.6M | ||
| TOTAL ASSETS | $6.5M | $5.8M | ||
| Accounts payable and accrued expenses | $199.0K | $992.0K | ||
| Total Current Liabilities | $199.0K | $992.0K | ||
| Common stock, par value $0.001, 100,000,000 shares authorized; 20,821,353 and 13,736,597 shares issued and outstanding, respectively; | $21.0K | $14.0K | ||
| Additional paid-in capital | $20.6M | $13.6M | ||
| Accumulated deficit | -$14.3M | -$8.8M | ||
| Total Shareholders Equity | $6.3M | $4.8M | -$2.1M | |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $6.5M | $5.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | 20.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 20.8M shares | 13.7M shares | ||
| Common stock, shares outstanding | 20.8M shares | 13.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$5.4M | -$2.6M |
| Amortization of intangible asset | $160.0K | $160.0K |
| Amortization of vendor advances | $2.2M | |
| Amortization of debt discount | $154.0K | |
| Fair value of vested restricted stock units | $482.0K | $218.0K |
| Fair value of common shares issued in connection with the conversion of accounts payable | $670.0K | |
| Fair value of warrants issued in connection with convertible notes payable | $29.0K | |
| Gain on settlement of accounts payable | -$599.0K | |
| Vendor advances | -$2.4M | |
| Prepaid expenses and other current assets | -$13.0K | -$30.0K |
| Accounts payable and accrued expenses | -$793.0K | $404.0K |
| Net cash used in operating activities | -$3.4M | -$4.0M |
| Proceeds from the sale and exercise of prefunded warrants | $3.1M | |
| Proceeds from the equity line of credit | $3.6M | |
| Proceeds from common stock issued for cash in connection with the closing of the initial public offering | $5.5M | |
| Proceeds from notes payable - officers | $142.0K | |
| Repayment of notes payable - officers | -$142.0K | |
| Payment of deferred offering costs | -$390.0K | |
| Net cash provided by financing activities | $6.7M | $5.1M |
| Net increase in cash and cash equivalents | $3.2M | $1.2M |
| Interest paid | $3.0K | |
| Common shares issued for deferred offering costs | $327.0K | $1.4M |
| Common shares issued for vendor advances | $157.0K | $500.0K |
| Reclassification of deferred offering costs to shareholders equity | $614.0K | $872.0K |
| Conversion of convertible notes payable and accrued interest to shareholders equity | $884.0K | |
| Conversion of accounts payable to shareholders equity | $1.3M | |
| Conversion of amounts due to related parties to shareholders equity | $4.0K | |
| Issuance of convertible notes payable recorded as debt discount | $49.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Kairos Pharma, LTD., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerJohn S. Yu Sep 24, 2024 to now8
- ChairJohn S. Yu Sep 24, 2024 to now8
Board members and other officers (6)
- Chief Scientific OfficerNeil Bhowmick Sep 24, 2024 to now9
- VP of Research and DevelopmentRamachandran Murali Sep 24, 2024 to now10
- Board memberRahul Singhvi Apr 30, 2025 to now11
- Board memberHansoo Michael Keyoung Sep 24, 2024 to now12
- Board memberHyun W. Bae Sep 24, 2024 to now13
- Board memberRosemary Mazanet Sep 24, 2024 to now14
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Chief Financial OfficerDoug S. Samuelson named Apr 27, 2023 to Jan 28, 202515
Timeline
- Sep 24, 2024New chief executive John S. Yu becomes CEO8
Filings
123 filings to the SEC since October 2021: 4 annual reports, 6 quarterly reports, 32 major events, 21 insider forms, 2 large holders, 2 private raises, 56 other. The latest 20:
- Oct 6, 20268-K EDGAR
- Sep 14, 20268-K EDGAR
- Aug 21, 20268-K EDGAR
- Aug 12, 202610-Q EDGAR
- Jul 22, 20268-K EDGAR
- Jul 15, 20268-K EDGAR
- Jun 30, 20268-K EDGAR
- Jun 4, 20268-K EDGAR
- May 26, 2026DEFA14A EDGAR
- May 22, 2026ARS EDGAR
- May 22, 2026DEF 14A EDGAR
- May 18, 20268-K EDGAR
- May 13, 202610-Q EDGAR
- May 11, 2026PRE 14A EDGAR
- Apr 1, 2026424B3 EDGAR
- Apr 1, 2026424B3 EDGAR
- Mar 31, 202610-K EDGAR
- Mar 2, 20268-K EDGAR
- Feb 26, 20268-K EDGAR
- Jan 23, 2026EFFECT EDGAR
The 123 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | Murali RamachandranVP of Research and Development | Buy | 200 | $1.59 | $318 | Form 4 |
| Nov 22, 2024 | Samuelson DougChief Financial Officer | Buy | 2,500 | $1.50 | $3.8K | Form 4 |
| Nov 20, 2024 | Yu John SCEO and Chairman | Buy | 4,000 | $1.44 | $5.8K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings May 15, 2025 to Aug 14, 202516
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARJohn S. Yu, Chief executive officer
- 9
- 10
- 11SEC EDGARRahul Singhvi, Board member
- 12SEC EDGARHansoo Michael Keyoung, Board member
- 13SEC EDGARHyun W. Bae, Board member
- 14SEC EDGARRosemary Mazanet, Board member
- 15
- 16